JAK2 and glioblastoma: Here, we show that JAK2/STAT3 inhibition with pacritinib is highly effective against BTICs in vitro, and not influenced by the status of common GBM molecular alterations including MGMT promoter methylation, EGFR, PTEN, TP53, NF1, and CDKN2A mutations.